Seventy consenting adult patients ( seropositive for IgM/IgG anti-CHIK antibody ) with early persistent musculoskeletal pain and arthritis were randomized into a 24-week , 2-arm , parallel efficacy trial of CQ ( 250 mg/day ) and meloxicam ( 7.5 mg/day ) .